싸이토젠

217330KOSDAQ자연과학 및 공학 연구개발업

48.5 / 100

Reference Date: 2026-06-10

Financial Score17.0 / 40

News Sentiment17.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Plunged 35.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

CytoGen focuses on liquid biopsy platforms based on CTC (Circulating Tumor Cells) technology, offering services such as supporting anti-cancer drug development, precision medicine, and health supplement sales. Key business areas include companion diagnostics development with pharmaceutical companies, medical device distribution, and health supplement sales, while also expanding globally through research and international collaborations.

Number of Employees

39people

Average Salary

64.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

2.59Industry Average 3.244.0Point

In line with industry avg

ROE

-29.06Industry Average -32.093.5Point

Below industry avg

Debt Ratio

31.95Industry Average 7.310.0Point

4.4x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲190.7% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲16.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -38.7% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 70

Neutral
싸이토젠, 52억 규모 전환사채권 발행 결정
싸이토젠이 운영자금 조달을 위해 전환사채 발행을 결정했으나, 구체적인 시장 영향은 제한적이다.
Positive
싸이토젠, 1분기 매출 64억원…전년 대비 실적 개선세 '뚜렷'
싸이토젠의 1분기 매출이 전년 대비 14% 증가하며 실적 개선이 뚜렷하게 나타났다.

Detailed Momentum

52-week position3.0Point

52w lower range (24%)

Current 4,025Won52-week high 9,42052-week low 2,320

1-month return0.0Point

1m -35.19% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral[기재정정]주식매수선택권부여에관한신고2026-06-09
Neutral주주명부폐쇄기간또는기준일설정2026-06-09
Neutral주주총회소집결의 (임시주주총회)2026-06-09
Neutral증권발행결과(자율공시) (제7회차 CB)2026-05-26
Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-05-20